Free Trial

ProKidney (PROK) Competitors

ProKidney logo
$1.70 +0.06 (+3.33%)
(As of 10:31 AM ET)

PROK vs. DNAB, DNAD, VPCB, FLYA, LGST, NAMS, CNTA, IRON, HRMY, and EVO

Should you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Social Capital Suvretta Holdings Corp. II (DNAB), Social Capital Suvretta Holdings Corp. IV (DNAD), VPC Impact Acquisition Holdings II (VPCB), SOAR Technology Acquisition (FLYA), Semper Paratus Acquisition (LGST), NewAmsterdam Pharma (NAMS), Centessa Pharmaceuticals (CNTA), Disc Medicine (IRON), Harmony Biosciences (HRMY), and Evotec (EVO).

ProKidney vs.

ProKidney (NASDAQ:PROK) and Social Capital Suvretta Holdings Corp. II (NASDAQ:DNAB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProKidneyN/AN/A-$35.47M-$0.55-3.00
Social Capital Suvretta Holdings Corp. IIN/AN/A$2.74MN/AN/A

ProKidney has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Social Capital Suvretta Holdings Corp. II has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500.

51.6% of ProKidney shares are held by institutional investors. Comparatively, 76.6% of Social Capital Suvretta Holdings Corp. II shares are held by institutional investors. 41.5% of ProKidney shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, ProKidney had 4 more articles in the media than Social Capital Suvretta Holdings Corp. II. MarketBeat recorded 4 mentions for ProKidney and 0 mentions for Social Capital Suvretta Holdings Corp. II. ProKidney's average media sentiment score of 0.67 beat Social Capital Suvretta Holdings Corp. II's score of 0.00 indicating that ProKidney is being referred to more favorably in the media.

Company Overall Sentiment
ProKidney Positive
Social Capital Suvretta Holdings Corp. II Neutral

ProKidney's return on equity of 0.00% beat Social Capital Suvretta Holdings Corp. II's return on equity.

Company Net Margins Return on Equity Return on Assets
ProKidneyN/A N/A -10.24%
Social Capital Suvretta Holdings Corp. II N/A -73.34%2.13%

ProKidney currently has a consensus target price of $4.50, indicating a potential upside of 172.73%. Given ProKidney's stronger consensus rating and higher possible upside, equities research analysts plainly believe ProKidney is more favorable than Social Capital Suvretta Holdings Corp. II.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProKidney
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Social Capital Suvretta Holdings Corp. II
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

ProKidney received 8 more outperform votes than Social Capital Suvretta Holdings Corp. II when rated by MarketBeat users.

CompanyUnderperformOutperform
ProKidneyOutperform Votes
8
57.14%
Underperform Votes
6
42.86%
Social Capital Suvretta Holdings Corp. IIN/AN/A

Summary

ProKidney beats Social Capital Suvretta Holdings Corp. II on 9 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PROK vs. The Competition

MetricProKidneyBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$477.96M$2.93B$5.06B$8.82B
Dividend YieldN/A1.89%5.18%4.07%
P/E Ratio-3.0045.61126.3217.81
Price / SalesN/A359.341,179.2574.56
Price / CashN/A160.0933.8632.53
Price / Book-0.343.734.684.68
Net Income-$35.47M-$41.63M$119.54M$226.08M
7 Day Performance-23.26%-4.73%-1.83%-1.04%
1 Month Performance-11.76%-6.53%-3.60%1.04%
1 Year Performance-11.29%25.63%31.91%26.28%

ProKidney Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PROK
ProKidney
2.5946 of 5 stars
$1.71
+3.3%
$4.50
+163.9%
-6.3%$493.89MN/A-3.103News Coverage
DNAB
Social Capital Suvretta Holdings Corp. II
N/A$10.35
+0.1%
N/A+0.0%$330.06MN/A0.004
DNAD
Social Capital Suvretta Holdings Corp. IV
N/A$10.35
flat
N/A+0.0%$330.06MN/A0.004
VPCB
VPC Impact Acquisition Holdings II
N/A$10.28
flat
N/A+0.0%$328.55MN/A0.007
FLYA
SOAR Technology Acquisition
N/A$10.41
-0.4%
N/A+0.0%$319.24MN/A0.002,021High Trading Volume
LGST
Semper Paratus Acquisition
N/A$4.51
flat
N/A-58.9%$71.35MN/A0.002,021Gap Up
IRON
Disc Medicine
3.1676 of 5 stars
$63.33
+1.2%
$85.80
+35.5%
+22.4%$1.88BN/A0.0078Insider Trade
Analyst Revision
CNTA
Centessa Pharmaceuticals
4.06 of 5 stars
$16.53
-1.3%
$25.83
+56.3%
+144.7%$1.87B$6.85M0.0072
HRMY
Harmony Biosciences
4.7919 of 5 stars
$32.68
-0.3%
$47.00
+43.8%
+18.1%$1.86B$582.02M15.64200
EVO
Evotec
1.9292 of 5 stars
$5.23
-1.3%
$5.93
+13.4%
-49.7%$1.85B$845.74M0.005,061
TARS
Tarsus Pharmaceuticals
1.8691 of 5 stars
$45.77
-1.7%
$54.20
+18.4%
+166.2%$1.75B$17.45M-12.2350Analyst Revision

Related Companies and Tools


This page (NASDAQ:PROK) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners